RedHill Biopharma Ltd. (RDHL)
Pre-market:
| Previous close | 0.4289 |
| Open | 0.4004 |
| Bid | 0.4118 x 200 |
| Ask | 0.4218 x 200 |
| Day's range | 0.4000 - 0.4309 |
| 52-week range | 0.2570 - 3.2800 |
| Volume | |
| Avg. volume | 707,903 |
| Market cap | 13.381M |
| Beta (5Y monthly) | 3.46 |
| PE ratio (TTM) | 0.10 |
| EPS (TTM) | 4.0000 |
| Earnings date | 10 Jun 2024 - 14 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 760.00 |
PR NewswireRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D
Simply Wall St.RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
RedHill Biopharma ( NASDAQ:RDHL ) Full Year 2023 Results Key Financial Results Net income: US$23.9m (up from US$71.7m...
- PR Newswire
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full year 2023 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2023.
